Therefore, determining genes that can affect cellular drug resistance as well as the stability of the EGFR protein is highly important for the treatment of NSCLC (Herbst et al., 2018; Tian et al., 2022). This evidence concerns the gene EGFR and non-small cell lung carcinoma.